Compass Therapeutics
CMPX
201 hedge funds and large institutions have $919M invested in Compass Therapeutics in 2026 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 75 increasing their positions, 48 reducing their positions, and 19 closing their positions.
1,626% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $1.11M
163% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 19
56% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 48
16% more funds holding
Funds holding: 173 → 201 (+28)
3.91% more ownership
Funds ownership: 92.29% → 96.2% (+3.9%)
4% more capital invested
Capital invested by funds: $881M → $919M (+$37.6M)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$23.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.8M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$12.2M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$11.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$24.6M |
| 2 |
Millennium Management
New York
|
-$13.1M |
| 3 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
-$7.6M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7.56M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$6.79M |
CMPX Hedge Fund Activity: Q1 2026 in Review
201 of the 8,190 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q1 2026, worth a combined $919M — up 4.3% from $881M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new CMPX positions and 19 closed out — a net gain of 31 holders — while 75 added to existing stakes and 48 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $23.4M. The largest seller was Blackstone Inc, cutting an estimated $24.6M.
- 201 institutional investors held Compass Therapeutics (CMPX) as of Q1 2026, up from 173 in Q4 2025.
- Funds reported $919M of Compass Therapeutics stock for Q1 2026, up 4.3% quarter-over-quarter.
- 50 funds opened new Compass Therapeutics positions in Q1 2026 and 19 closed out, a net change of +31 holders.
- The largest Compass Therapeutics buyer in Q1 2026 was Adage Capital Partners, an estimated $23.4M added.
- The largest Compass Therapeutics seller in Q1 2026 was Blackstone Inc, an estimated $24.6M sold.
Based on aggregated 13F filings for Q1 2026.